C Le Pechoux
Overview
Explore the profile of C Le Pechoux including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
124
Citations
2529
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Levy A, Clemenson C, Mondini M, Ngo C, Verret B, Faron M, et al.
Ann Oncol
. 2025 Feb;
PMID: 40010567
No abstract available.
2.
Bourbonne V, Levy A, Khalifa J, Antoni D, Blais E, Darreon J, et al.
Cancer Radiother
. 2024 Jan;
28(1):36-48.
PMID: 38228422
In recent years, the development of both medical imaging and new systemic agents (targeted therapy and immunotherapy) have revolutionized the field of oncology, leading to a new entity: oligometastatic disease....
3.
Llacer-Moscardo C, Moureau-Zabotto L, Ollivier L, Helfre S, Ducassou A, Bonvalot S, et al.
Cancer Radiother
. 2024 Jan;
28(1):93-102.
PMID: 38212215
Soft tissue sarcomas are a rare and heterogeneous disease. For localized disease, treatment is based on surgery and radiotherapy with or without chemotherapy depending on risk factors. Upfront metastases are...
4.
Acidi B, Faron M, Mir O, Levy A, Ghallab M, Haddag-Miliani L, et al.
Prog Urol
. 2023 Oct;
33(15-16):1026-1032.
PMID: 37858378
Introduction: Surgical resection is the current standard of care for retroperitoneal sarcoma (RPS). Recent data suggests that up to 5% of patient have incomplete (R2) resection. The exact reason why...
5.
Khalifa J, Levy A, Sauvage L, Thureau S, Darreon J, Le Pechoux C, et al.
Cancer Radiother
. 2023 Aug;
28(1):22-35.
PMID: 37574329
Metastatic lung cancer classically portends a poor prognosis. The management of metastatic lung cancer has dramatically changed with the emergence of immune checkpoint inhibitors, targeted therapy and due to a...
6.
Bonvalot S, Roland C, Raut C, Le Pechoux C, Tzanis D, Frezza A, et al.
Eur J Surg Oncol
. 2022 May;
49(6):1061-1067.
PMID: 35599138
Until recently, the recommendation for primary retroperitoneal sarcomas (RPS) was to perform a complete en-bloc gross excision, (neo) adjuvant treatments being options which were not validated by randomized studies, with...
7.
Ngo C, Grinda T, Boileve A, Levy A, Le Pechoux C, Haddag L, et al.
Ann Oncol
. 2022 May;
33(8):848-850.
PMID: 35568279
No abstract available.
8.
Tredaniel J, Barlesi F, Le Pechoux C, Lerouge D, Pichon E, Le Moulec S, et al.
Cancer Radiother
. 2022 Mar;
26(5):670-677.
PMID: 35260342
Purpose: Roughly 20% of patients with non-small-cell lung cancer exhibit locally advanced, unresectable, stage III disease. Concurrent platinum-based chemoradiotherapy is the backbone treatment, which is followed by maintenance immunotherapy, yet...
9.
Nassif E, Blay J, Massard C, Dufresne A, Brahmi M, Cassier P, et al.
ESMO Open
. 2022 Mar;
7(2):100425.
PMID: 35255445
Background: The prognosis of patients with advanced soft-tissue sarcomas (STS) remains dismal, and systemic therapeutic options are limited. Early phase trials are becoming increasingly safe and effective. This study aimed...
10.
Le Pechoux C, Llacer C, Sargos P, Moureau-Zabotto L, Ducassou A, Sunyach M, et al.
Cancer Radiother
. 2021 Dec;
26(1-2):377-387.
PMID: 34961656
We present the update of the recommendations of the French society of radiation oncology on soft tissue sarcomas. Currently, the initial management of sarcomas is very important as it may...